marijuana stocks news

Inergetics, Inc. (NRTI)

 
Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 558   430   524   480  
Cost of Revenue 438 360 310 363
Gross Profit 120   70   213   117  
Operating Expenses
Research Development 0 11 9 4
Selling General and Administrative 1,430 1,294 1,556 3,141
Non Recurring – – – –
Others – – – –
Total Operating Expenses – – – –
Operating Income or Loss (1,310) (1,235) (1,351) (3,028)
Income from Continuing Operations
Total Other Income/Expenses Net 3,245 (3,190) 509 (1,132)
Earnings Before Interest And Taxes 1,935 (4,425) (842) (4,160)
Interest Expense 241 (8) 401 367
Income Before Tax 1,694 (4,417) (1,243) (4,527)
Income Tax Expense (376) 2 – –
Minority Interest – – – –
Net Income From Continuing Ops 1,875 (4,418) (1,240) (4,511)
Non-recurring Events
Discontinued Operations – – – –
Extraordinary Items – – – –
Effect Of Accounting Changes – – – –
Other Items – – – –
Net Income 2,070   (4,418) (1,243) (4,527)
Preferred Stock And Other Adjustments (332) (459) (322) (258)
Net Income Applicable To Common Shares 1,738   (4,878) (1,564) (4,785)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$LXRP Webcast Thursday 12-18

Lexaria to Present Webcast on Thursday December 18 Lexaria, Corp. to Present…

Leafbuyer Technologies, Inc. (LBUY) Announces Letter of Intent to Acquire Leading Mobile Ordering App

Leafbuyer Technologies Announces Letter of Intent to Acquire Leading Mobile Ordering App…

$TRTC Gives Update on Nevada Medical Cannabis and National Initiatives

Terra Tech Gives Update on Nevada Medical Cannabis and National Initiatives Irvine,…

Cara Therapeutics, Inc. (CARA) Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board…